ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1357

The ANCA-Associated Vasculitis Patient-Reported Outcome (AAV-PRO) Captures Depression and Health-Related Quality of Life More Than Disease Activity and Damage

Annika Maunz1, Joerg Henes2, Joanna Robson3, Johann Jacoby4, Bernhard Hellmich5 and Christian Löffler6, 1Medius Kliniken - Teaching Hospital University of Tübingen, Kirchheim-Teck, Tübingen, Germany, 2Center for Interdisciplinary Clinical Immunology, Rheumatology and Auto-inflammatory Diseases (INDIRA), University Hospital Tübingen, Tübingen, Germany, 3UWE Bristol, Bristol, United Kingdom, 4University Hospital Tübingen, Institute for Clinical Epidemiology and Applied Biometry, Tübingen, Germany, 5Klinik für Innere Medizin, Rheumatologie & Immunologie, Medius Kliniken, Universität Tübingen, Plochingen, Germany, 6Medius Kliniken - Teaching Hospital University of Tübingen,, Kirchheim Teck, Germany

Meeting: ACR Convergence 2022

Keywords: ANCA associated vasculitis, depression, Disease Activity, Patient reported outcomes, SF36

  • Tweet
  • Email
  • Print
Session Information

Date: Sunday, November 13, 2022

Title: Patient Outcomes, Preferences, and Attitudes Poster II

Session Type: Poster Session C

Session Time: 1:00PM-3:00PM

Background/Purpose: The ANCA-associated vasculitis patient-reported outcome (AAV-PRO) is a new disease-specific PRO developed to capture the impact of having AAV and dealing with its treatment (Robson et al., 2018). It therefore may be more specific to health-related quality of life (HRQoL) in this disease than generic measures. As a profile measure the AAV-PRO contains six different domains: Organ-specific symptoms (OSS), systemic symptoms severity (SSS), treatment side effects (TSE), social and emotional impact (SEI), concerns about the future (CAF), and physical function (PF). The aim of this study was to explore the association of disease activity, damage, depression, HRQoL, treatment, relapses, and organ manifestations with the patient’s AAV-PRO domain scores.

Methods: AAV-PRO, Beck’s depression inventory (BDI), Short Form 36 (SF36), Birmingham Vasculitis Activity Score (BVAS) and Vasculitis Damage Index (VDI) were completed at baseline (t1) and after 3-6 months (t2). In addition, patient data such as age, diagnosis, therapies, relapses, and organ manifestations were recorded. Data were analyzed by t-tests and correlation-based regression analyses.

Results: 156 patients with AAV participated (table 1). Median AAV-PRO domain scores were higher in patients reporting “active disease” compared to patients reporting “in remission” (p< 0.001). When the patient cohort was divided based on objective disease activity (BVAS ≥ 1) the results of mean differences were heterogenous. The strongest predictors found in the regression analyses for each AAV-PRO domain are depicted in Figure 1. Detailed results are shown in Table 2. OSS was mainly predicted by SF36 ‘pain’ and the number of relapses. For SSS, it was SF36 ‘pain’ and ‘energy/fatigue’. The strongest predictor of TSE was the BDI. SEI and CAF were chiefly predicted by the BDI and SF36 ’emotional well-being’. Overall, the strongest association was seen between PF and SF36 ‘physical functioning’. In regression analyses predicting the BDI by the AAV-PRO domains, SEI was found to have high predictive power for the BDI. Substantial relationships were also found when regressing the SF36 subdomains on the AAV-PRO domains. There were no significant relationships between the AAV-PRO domains and BVAS, VDI, therapies or organ manifestations. This pattern of results held both at t1 and t2.

Conclusion: We confirm the previously reported strong association of AAV-PRO domain scoring to the patient’s self-evaluation in a German AAV cohort. Our data show convergent validity of all AAV-PRO subdomains with the established questionnaires BDI and SF-36. However, none of the AAV-PRO domains are markedly related to objective parameters of disease such as BVAS and VDI. Thus, we regard the AAV-PRO as a valuable addition that might complement traditional endpoints like activity and damage in future clinical trials. The replicability of the current results should be assessed in the future, possibly with patients with more active vasculitis and with a larger sample that provides more power.

Supporting image 1

Supporting image 2

Supporting image 3


Disclosures: A. Maunz, None; J. Henes, Boehringer Ingelheim; J. Robson, None; J. Jacoby, None; B. Hellmich, AbbVie, Amgen, AstraZeneca, Bristol-Myers Squibb (BMS), Boehringer-Ingelheim, Chugai, GlaxoSmithKline (GSK), InflaRx, Janssen, MSD, Novartis, Pfizer, Phadia, Roche, Vifor; C. Löffler, None.

To cite this abstract in AMA style:

Maunz A, Henes J, Robson J, Jacoby J, Hellmich B, Löffler C. The ANCA-Associated Vasculitis Patient-Reported Outcome (AAV-PRO) Captures Depression and Health-Related Quality of Life More Than Disease Activity and Damage [abstract]. Arthritis Rheumatol. 2022; 74 (suppl 9). https://acrabstracts.org/abstract/the-anca-associated-vasculitis-patient-reported-outcome-aav-pro-captures-depression-and-health-related-quality-of-life-more-than-disease-activity-and-damage/. Accessed .
  • Tweet
  • Email
  • Print

« Back to ACR Convergence 2022

ACR Meeting Abstracts - https://acrabstracts.org/abstract/the-anca-associated-vasculitis-patient-reported-outcome-aav-pro-captures-depression-and-health-related-quality-of-life-more-than-disease-activity-and-damage/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology